Format

Send to

Choose Destination
Sci Transl Med. 2019 Jan 30;11(477). pii: eaat3356. doi: 10.1126/scitranslmed.aat3356.

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay.

Author information

1
Department of Immunopathology, Sanquin Research, 1066 CX Amsterdam, Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands.
2
Amsterdam Rheumatology and immunology Center, Reade, 1056 AB Amsterdam, Netherlands.
3
Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, VU University Medical Center, 1081 HV Amsterdam, Netherlands.
4
Amsterdam Rheumatology and Immunology Center, Amsterdam UMC, Academic Medical Center, 1105 AZ Amsterdam, Netherlands.
5
Department of Epidemiology and Biostatistics, VU University Medical Center, 1081 HV Amsterdam, Netherlands.
6
Pfizer Inc., Collegeville, PA 19426, USA.
7
St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, Kings College London, SE1 9RT London, UK.
8
Department of Immunopathology, Sanquin Research, 1066 CX Amsterdam, Netherlands, and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands. t.rispens@sanquin.nl.

Abstract

Patients with rheumatoid arthritis (RA) can be successfully treated with tumor necrosis factor (TNF) inhibitors, including the monoclonal antibody adalimumab. Once in remission, a proportion of patients can successfully discontinue treatment, indicating that blocking TNF is no longer required for disease control. To explore the dynamics of circulating TNF during adalimumab treatment, we developed a competition enzyme-linked immunosorbent assay that can quantify TNF in the presence of large amounts of TNF inhibitor, i.e., a "drug-tolerant" assay. In 193 consecutive adalimumab-treated patients with RA, we demonstrated that circulating TNF increased in average of >50-fold upon treatment and reached a stable concentration in time for most patients. A similar increase in TNF was found in 30 healthy volunteers after one dose of adalimumab. This implies that TNF in circulation during anti-TNF treatment is not primarily associated with disease activity. During treatment, TNF was in complex with adalimumab and could be recovered as inactive 3:1 adalimumab-TNF complexes. No quantitative association was found between TNF and adalimumab concentrations. Low TNF concentrations at week 4 were associated with a higher frequency of antidrug antibodies (ADAs) at subsequent time points, less frequent methotrexate use at baseline, and less frequent remission after 52 weeks. Also in healthy volunteers, early low TNF concentrations are associated with ADAs. In conclusion, longitudinal TNF concentrations are mostly stable during adalimumab treatment and may therefore not predict successful treatment discontinuation. However, early low TNF is strongly associated with ADA formation and may be used as timely predictor of nonresponse toward adalimumab treatment.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center